ESMO SUMMIT LATIN AMERICA 2019 Breast Cancer Clinical Cases - - PowerPoint PPT Presentation

▶
esmo summit latin america 2019
SMART_READER_LITE
LIVE PREVIEW

ESMO SUMMIT LATIN AMERICA 2019 Breast Cancer Clinical Cases - - PowerPoint PPT Presentation

Oct 26, 2022 239 likes •578 views

ESMO SUMMIT LATIN AMERICA 2019 Breast Cancer Clinical Cases Enrique Soto Prez de Celis MD, MSc Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn Mxico City, Mexico CONFLICT OF INTEREST DISCLOSURE Dr. Soto Prez de

slide-1
SLIDE 1

ESMO SUMMIT LATIN AMERICA 2019

Breast Cancer Clinical Cases

Enrique Soto Pérez de Celis MD, MSc Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán México City, Mexico

slide-2
SLIDE 2

CONFLICT OF INTEREST DISCLOSURE

  • Dr. Soto Pérez de Celis has no financial conflicts of interest to disclose
slide-3
SLIDE 3

CASE 1

A young woman with triple negative breast cancer

slide-4
SLIDE 4

CASE 1

A young woman with triple negative breast cancer

  • 32 year old woman
  • One aunt with breast cancer after age 50
  • No history of pregnancy
  • No alcohol consumption
  • First menstrual period at age 14, has never used oral contraception
  • No other comorbidities
slide-5
SLIDE 5

CASE 1

A young woman with triple negative breast cancer

  • April 2018: self palpated a tumor on her left breast
  • Ultrasound: septated lesion in the left breast (29 x 11 x 21mm). BIRADS 4A. No

suspicious axillary lymph nodes detected

  • Biopsy: infiltrating ductal carcinoma, high grade, ER-, PR-, HER2++, Ki67 60%.

 HER2 FISH: HER2 neu/CEN 17:1.45 (not amplified)

  • A clip was placed in the tumor and sequential neoadjuvant chemotherapy was

planned

slide-6
SLIDE 6

CASE 1

Questions

1.

Is neoadjuvant chemotherapy indicated in all triple negative tumors, regardless of size and lymph node status?

2.

What are the probabilities of this patient having a genetic predisposition mutation for breast cancer?

3.

The patient wishes to become pregnant in the future but cannot afford cryopreservation, what other options are available?

slide-7
SLIDE 7

CASE 1

A young woman with triple negative breast cancer

  • The patient received neoadjuvant chemotherapy

4 cycles of dose dense AC

12 cycles of weekly paclitaxel

  • LHRH analogues were used during chemotherapy
  • Breast conserving surgery with sentinel lymph node was performed after

completion of NACT

  • Pathological review: ductal infiltrating carcinoma in the breast (10 x 6mm). ER-, PR-

, HER2-, Ki67 25%. Residual Cancer Burden (RCB) 1.909 (RCB-II)

slide-8
SLIDE 8

CASE 1

Questions

1.

Is it necessary to repeat the determination of HR and HER2 status after neoadjuvant treatment?

2.

Would you offer additional adjuvant treatment to this patient?

3.

What type of long term complications can we expect after completing treatment, and what type of follow up is needed?

4.

Are there ongoing clinical trials of immunotherapy in this scenario?

slide-9
SLIDE 9

CASE 2

A postmenopausal woman with recurrent stage IV HER2-positive breast cancer

slide-10
SLIDE 10

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • 59 year old woman
  • Father with pancreatic cancer, two paternal aunts with breast cancer at age 40
  • Two pregnancies
  • No alcohol consumption
  • First menstrual period at age 15, menopause at age 52
  • No other comorbidities
slide-11
SLIDE 11

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • June 2015: self palpated a tumor on her right breast
  • Ultrasound: tumor in the right breast (24 x 20 x 27mm). Two suspicious axillary

lymph nodes detected. BIRADS 4A

  • Biopsy: infiltrating ductal carcinoma, high grade, ER-, PR-, HER2+++, Ki67 10%.

 FNA of the axillary lymph nodes positive for carcinoma

  • Staging revealed no signs of metastatic disease
slide-12
SLIDE 12

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • Received neoadjuvant treatment with trastuzumab plus weekly paclitaxel followed

by four cycles of AC, without radiological response in breast/axilla

  • She underwent BCS plus axillary lymph node dissection

 Residual tumor 19 x 14 x 0.8 cm  Two positive lymph nodes  HR-, HER2+++

  • Trastuzumab was continued until completing a year (10/2016), radiotherapy was

provided to the breast and axilla

slide-13
SLIDE 13

CASE 2

Questions

1.

What is the ideal neoadjuvant chemotherapy for HER2+ breast cancer? Should pertuzumab be added in all cases?

2.

Should this patient be tested for genetic predisposition to breast cancer? Would it alter management?

3.

Should the patient receive adjuvant therapy after initial treatment (with the benefit

  • f hindsight)?
slide-14
SLIDE 14

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • 16 months after completing trastuzumab she had a recurrence on the skin of the

right breast. Biopsy showed IDC, HR-, HER2+++. Unresectable. PET/CT was negative for other metastatic sites

  • Treatment with pertuzumab+docetaxel+trastuzumab was administered for 6 cycles

with partial response

  • Mastectomy was performed in October 2018 with residual HER2+ disease.

Trastuzumab was restarted

slide-15
SLIDE 15

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

slide-16
SLIDE 16

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • 16 months after completing trastuzumab she had a recurrence on the skin of the

right breast. Biopsy showed IDC, HR-, HER2+++. Unresectable. PET/CT was negative for other metastatic sites

  • Treatment with pertuzumab+docetaxel+trastuzumab was administered for 6 cycles

with partial response

  • Mastectomy was performed in October 2018 with residual HER2+ disease.

Trastuzumab was restarted

slide-17
SLIDE 17

CASE 2

Questions

1.

Should trastuzumab be continued after a local recurrence is treated with “curative” intent?

2.

Should the patient receive “adjuvant” therapy with TDM1 after rescue mastectomy?

slide-18
SLIDE 18

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • Two months after mastectomy a PET/CT showed FDG uptake in a right-sided

parasternal node, contralateral axillary lymph nodes, and the left breast

  • Breast biopsy: DCI, HR-, HER2+++, Ki67%. Parasternal node and left axillary

nodes with metastatic disease

  • Genetic testing was ordered, the result is pending
slide-19
SLIDE 19

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

slide-20
SLIDE 20

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

slide-21
SLIDE 21

CASE 2

A postmenopausal woman with recurrent stage IV HER2+ breast cancer

  • Two months after mastectomy a PET/CT showed FDG uptake in a right-sided

parasternal node, contralateral axillary lymph nodes, and the left breast

  • Breast biopsy: DCI, HR-, HER2+++, Ki67%. Parasternal node and left axillary

nodes with metastatic disease

  • Genetic testing was ordered, the result is pending
slide-22
SLIDE 22

CASE 2

Questions

1.

What now?

a)

TDM-1?

b)

Locoregional control?

c)

What other options could be utilized in the future?

2.

Would the finding of a mutation from the beginning have altered the course of the disease?

slide-23
SLIDE 23

CASE 3

An older adult with screening- detected hormone receptor positive disease

slide-24
SLIDE 24

CASE 3

An older adult with screening-detected hormone receptor positive disease

  • 75 year old female
  • No personal or family history of cancer
  • Three pregnancies
  • No alcohol consumption
  • First menstrual period at age 15, menopause age 45. Did not use hormone

replacement therapy

  • Comorbidities: diabetes, hypothyroidism
slide-25
SLIDE 25

CASE 3

An older adult with screening-detected hormone receptor positive disease

  • October 2018: screening mammogram with a 12mm nodule in the left breast.

BIRADS 5

  • Ultrasound: left breast nodule (12mm). No suspicious axillary lymph nodes
  • Biopsy: infiltrating ductal carcinoma, Grade 1, ER 90%, PR 60%, HER2+, Ki67 10%
  • The patient underwent BCS plus SLNB

 Pathology: IDC 1.4cm, negative margins, ER 90%, PR 50%, 2/2 sentinel lymph

nodes with metastatic carcinoma

slide-26
SLIDE 26

CASE 3

An older adult with screening-detected hormone receptor positive disease

slide-27
SLIDE 27

CASE 3

An older adult with screening-detected hormone receptor positive disease

  • October 2018: screening mammogram with a 12mm nodule in the left breast.

BIRADS 5

  • Ultrasound: left breast nodule (12mm). No suspicious axillary lymph nodes
  • Biopsy: infiltrating ductal carcinoma, Grade 1, ER 90%, PR60%, HER2+, Ki67 10%
  • The patient underwent BCS plus SLNB

 Pathology: IDC 1.4cm, negative margins, ER 90%, PR 50%, 2/2 sentinel lymph

nodes with metastatic carcinoma

slide-28
SLIDE 28

CASE 3

Questions

1.

Was this patient a good candidate for a screening mammogram?

2.

Would primary endocrine therapy be an appropriate option for this patient?

3.

Is this patient a candidate for a gene signature test?

a)

Are gene signature tests cost-effective in developing countries?

b)

Can clinical models obviate the need for gene signature tests in some cases?

slide-29
SLIDE 29

0.6% of low clinical risk women in MINDACT (190/3337)

slide-30
SLIDE 30
slide-31
SLIDE 31

CASE 3

An older adult with screening-detected hormone receptor positive disease

  • The patient was started on adjuvant endocrine therapy with letrozole
  • Cytotoxic chemotherapy was omitted
  • She was also started on adjuvant conventional radiotherapy to the breast and axilla
slide-32
SLIDE 32

CASE 3

Questions

1.

Can this patient be considered “low clinical risk” without a complete axillary lymph node dissection?

a)

Is the evidence enough to omit chemotherapy in this patient?

2.

How long would you continue adjuvant treatment with hormonal therapy?

3.

What are the prospects for using targeted therapy for the adjuvant treatment of HR+ disease (such as CDK 4/6 inhibitors)?

4.

Is conventional fractionation of radiotherapy the preferred approach?

slide-33
SLIDE 33

THANK YOU